Te­va re­cruits Tal Zaks to its board, of­fer­ing $300K+ pay pack­age and seam­less tran­si­tion from Mod­er­na

4 years ago
People

J&J HIV shot fails, adding an­oth­er blow to decades-long ef­fort to curb epi­dem­ic

4 years ago
R&D

Covid-19 roundup: South Ko­re­an vac­cine to go up against As­traZeneca shot in small Phase III; CD­C's ACIP af­firms full ...

4 years ago
Coronavirus

A No­var­tis castoff drug gets new life at an At­las-backed start­up look­ing to blaze a trail in obe­si­ty

4 years ago
Financing
Startups

Lu­ca Santarel­li's Vec­tivBio buys out small Mass­a­chu­setts biotech, re­dou­bling fo­cus on meta­bol­ic dis­ease

4 years ago
Deals

Un­der with­er­ing fire, Gala­pa­gos founder and CEO On­no van de Stolpe is ex­it­ing top post

4 years ago
People

Spring­Works teams with Dana-Far­ber to test BC­MA com­bo; VBL restarts PhI­II tri­al af­ter FDA clears gene ther­a­py batch­es

4 years ago
News Briefing

Feng Zhang's lab de­vel­ops po­ten­tial break­through in RNA edit­ing de­liv­ery us­ing 'ul­tra­com­pact' ver­sions of Cas13

4 years ago
Discovery
Cell/Gene Tx

Flag­ship woos an­oth­er Big Phar­ma BD ex­ec to biotech. Red blood cell ther­a­pies any­one?

4 years ago
People

Re­im­burse­ment be­gins slow­ly for Bio­gen’s ex­pen­sive Alzheimer’s drug

4 years ago
Pharma

Pfiz­er says its JAK drug topped Dupix­ent in a head-to-head eczema test — but you'll have to wait on the da­ta

4 years ago
R&D

In $1B buy­out, Catal­ent takes on gum­my com­pa­ny to jump in­to a boom­ing mar­ket

4 years ago
Manufacturing

Covid-19 roundup: Duke de­mands Covid vac­cine — or else; FDA re­sumes Eli Lil­ly's mAb use in 22 states af­ter pause ...

4 years ago
Coronavirus

Founders of Tai­wanese biotech in­volved in steal­ing Genen­tech se­crets plead guilty to con­spir­a­cy

4 years ago
People
Pharma

Sanofi, Re­gen­eron bur­nish their block­buster Dupix­ent fran­chise with pos­i­tive re­sults in chil­dren with un­con­trolled ...

4 years ago
R&D
Pharma

A tiny biotech racks up an­oth­er PhI­II fail, crip­pling its share price

4 years ago
R&D

From bench to board­room: 20 of the most in­flu­en­tial bio­phar­ma R&D ex­ec­u­tives in drug de­vel­op­ment

4 years ago
People
R&D

Big mon­ey: Flag­ship's uber-plat­form play Laronde rakes in $440M to chase pro­gram­ma­ble 'eR­NA'

4 years ago
Financing
Cell/Gene Tx

The past and fu­ture of an­ti­bod­ies, as told through HIV; An­oth­er big phar­ma joins CD47 game; and more

4 years ago
Weekly

Roche pulls dan­gling ac­cel­er­at­ed ap­proval for Tecen­triq in triple-neg­a­tive breast can­cer

4 years ago
R&D
FDA+

As­traZeneca pro­motes on­col­o­gy ex­ec to CMO; Pfiz­er re­places re­tir­ing chief deal­mak­er as war chest ex­pands

4 years ago
Peer Review

EC ap­proves Bio­Marin drug as first treat­ment for chil­dren with com­mon form of dwarfism; Servi­er sN­DA wins ap­proval

4 years ago
News Briefing

Re­gen­eron, GSK see mas­sive spike in Covid-19 mAb de­mand as US de­bates buy­ing more

4 years ago
Coronavirus

Backed by Eli Lil­ly, a lit­tle-known and se­cre­tive Chi­nese biotech fills the tank as it heads to the clin­ic

4 years ago
Financing
First page Previous page 645646647648649650651 Next page Last page
A service from the Financial Times